

# BioArctic in 3 minutes

## BioArctic is an innovative Swedish biopharma company focusing on neurodegenerative diseases

The objective is to develop new treatments that target the causes of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and ALS.



## Developing selective antibodies

BioArctic's research portfolio consists primarily of selective antibodies for soluble pathogenic aggregates formed by misfolded proteins in the central nervous system.

## The first drug to slow Alzheimer's disease

Lecanemab is the world's first fully approved drug for early Alzheimer's disease that slows the progress of the disease and reduces cognitive degeneration. Lecanemab was invented by BioArctic, and has been outlicensed to the Japanese pharma company Eisai since 2007. BioArctic is entitled to sales' royalties based on global sales, milestone payments and co-promotion revenue in the Nordic region.

Lecanemab has been approved in the US, Japan and China under the brand name Leqembi®.



**15**  
research  
projects  
in BioArctic's diversified  
project portfolio.




## Nordic organization

During the year, BioArctic established operations in Denmark, Finland and Norway to enable a future launch of lecanemab in the Nordic region.



## Alzheimer's disease

Apart from lecanemab, which is an approved treatment for early Alzheimer's disease in the US, Japan and China, BioArctic is developing further antibodies against Alzheimer's disease to improve and expand the treatment options.



## BrainTransporter technology™

BioArctic's technology for actively transporting antibodies and other biological treatments across the blood-brain barrier has the potential to increase the efficacy of treatments that target the brain.



## Parkinson's disease

BioArctic has developed a portfolio of potential disease-modifying antibodies against misfolded alpha-synuclein, which is the protein that causes Parkinson's disease. In 2023, BioArctic decided to start preparing for a Phase 2a study with its most advanced antibody, exidavnemab (formerly BAN0805). The antibodies in the Parkinson's program also have potential for the treatment for Lewy body dementia and multiple system atrophy.



ND3014

ND-BT3814

## ALS

In its ND3014 and ND-BT3814 projects, BioArctic is engaged in developing selective antibodies targeted at TDP-43, a protein that is misfolded in ALS patients. The antibodies make it easier for the immune system to detect and eliminate the harmful aggregations of TDP-43, which is believed to slow disease progression and achieve a disease-modifying effect.

# TDP-43

## 88 employees

In 2023, BioArctic's operations and organization experienced significant growth. New and supplementary functions have been established, while subsidiaries for commercial operations were established in Denmark, Norway and Finland.